UCB Licenses Keppra, Cimzia Rights in Japan in €113M Deal
Belgian firm UCB SA licensed Japanese co-promotion rights to two drugs, Keppra and Cimzia, to Otsuka Pharmaceuticals Co. Ltd. in a deal that could be worth as much as €113 million (US$174 million) to UCB.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter